Medroxyprogesterone Acetate
"Medroxyprogesterone Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.
Descriptor ID |
D017258
|
MeSH Number(s) |
D04.210.500.745.745.654.829.395.700.500
|
Concept/Terms |
Medroxyprogesterone Acetate- Medroxyprogesterone Acetate
- Depo-Medroxyprogesterone Acetate
- Depo Medroxyprogesterone Acetate
- 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate
- 6 alpha Methyl 17alpha hydroxyprogesterone Acetate
- (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione
- Medroxyprogesterone 17-Acetate
- Medroxyprogesterone 17 Acetate
|
Below are MeSH descriptors whose meaning is more general than "Medroxyprogesterone Acetate".
Below are MeSH descriptors whose meaning is more specific than "Medroxyprogesterone Acetate".
This graph shows the total number of publications written about "Medroxyprogesterone Acetate" by people in this website by year, and whether "Medroxyprogesterone Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2005 | 1 | 0 | 1 |
2006 | 2 | 0 | 2 |
2007 | 2 | 0 | 2 |
2010 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Medroxyprogesterone Acetate" by people in Profiles.
-
Parker LA, Sullivan S, Cacho N, Krueger C, Mueller M. Effect of Postpartum Depo Medroxyprogesterone Acetate on Lactation in Mothers of Very Low-Birth-Weight Infants. Breastfeed Med. 2021 10; 16(10):835-842.
-
Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, Kim E, Yaffe MD, Boyd NF, Heiss G, McTiernan A, Chlebowski RT, Lane DS, Manson JE, Wactawski-Wende J, Pisano ED. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst. 2017 09 01; 109(9).
-
Dempsey A, Roca C, Westhoff C. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. Contraception. 2010 Sep; 82(3):250-5.
-
Gordon L, Thakur N, Atlas M, Januchowski R. Clinical inquiries. What hormonal contraception is most effective for obese women? J Fam Pract. 2007 Jun; 56(6):471-3.
-
Thurman AR, Livengood CH, Soper DE. Chronic endometritis in DMPA users and Chlamydia trachomatis endometritis. Contraception. 2007 Jul; 76(1):49-52.
-
Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006 Mar 20; 24(9):1409-14.
-
Thurman AR, Soper DE. Endometrial histology of Depomedroxyprogesterone acetate users: a pilot study. Infect Dis Obstet Gynecol. 2006; 2006:69402.
-
McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005 Sep 21; 97(18):1366-76.
-
Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL, Creasman WT. An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med. 1999 Jun-Aug; 44(4):186-92.